







































**Table 5: Medications**

	<b>Overall 819</b>	<b>Marmara 271 (33.1%)</b>	<b>Central Anatolia 111 (13.6%)</b>	<b>Aegean 120 (14.7%)</b>	<b>Mediterranean 102 (12.5%)</b>	<b>Black Sea 84 (10.2%)</b>	<b>Southeast Anatolia 66 (8%)</b>	<b>East Anatolia 65 (7.9%)</b>	<b>p</b>
<b>Angiotensin-converting enzyme inhibitor</b>	265 [32.4 (26.2-36.5)]	90 [33.2 (27.5-38.8)]	25 [22.5 (14.6-30.4)]	35 [29.2 (20.3-36.8)]	27 [26.5 (17.7-35.1)]	36 [42.9 (32-53.6)]	18 [27.3 (16.2-38.3)]	34 [52.3 (39.8-64.7)]	0.001
<b>Angiotensin receptor blocker</b>	228 [27.8 (23.1-31.9)]	84 [31 (25.4-36.5)]	24 [21.6 (13.8-29.4)]	32 [26.7 (18.8-34.9)]	30 [29.4 (20.4-38.4)]	20 [23.8 (14.5-33.1)]	17 [25.8 (14.9-36.6)]	21 [32.3 (20.6-43.9)]	0.524
<b>Beta-blocker</b>	452 [55.2 (49.1-61.3)]	166 [61.3 (55.4-67.1)]	59 [53.2 (43.7-62.5)]	66 [55.0 (46.4-64.5)]	53 [52.0 (42.1-61.7)]	48 [57.7 (46.3-67.9)]	33 [50.0 (37.6-62.4)]	27 [41.5 (29.2-53.8)]	0.109
<b>Aldosterone antagonists</b>	120 [14.7 (10.2-18.3)]	36 [13.3 (9.2-17.3)]	16 [14.4 (7.7-21)]	16 [13.3 (7.2-19.6)]	13 [11.7 (6.1-19.5)]	15 [17.9 (9.5-26.2)]	12 [18.2 (8.6-27.7)]	12 [18.5 (8.7-28.1)]	0.812
<b>Amiodarone</b>	14 [1.7 (0.2-2.5)]	4 [1.5 (0.3-2.9)]	3 [2.7 (0.3-5.7)]	2 [1.7 (0.6-4.0)]	1 [3.9 (0.9-7.1)]	0 (0)	1 [1.5 (0.1-4.5)]	0 (0)	0.389
<b>Nondihydropyridine calcium blockers</b>	102 [12.5 (8.4-15.6)]	34 [12.5 (8.5-16.5)]	10 [9.0 (3.6-14.4)]	16 [13.3 (7.2-19.6)]	20 [11.6 (11.7-17.4)]	4 [4.8 (0.1-9.4)]	14 [21.2 (11-31.3)]	4 [6.2 (1.1-12.1)]	0.007
<b>Dihydropyridine calcium blockers</b>	179 [21.9 (16.5-26.3)]	54 [19.9 (15.1-24.7)]	22 [19.8 (12.3-27.3)]	26 [21.7 (11.7-29.4)]	28 [27.5 (18.6-36.2)]	16 [19.0 (10.4-27.6)]	19 [28.8 (17.5-40)]	14 [21.5 (11.2-31.8)]	0.546
<b>Digoxin</b>	50 [6.1 (3.1-8.6)]	15 [5.5 (2.8-8.2)]	5 [4.5 (0.5-8.4)]	11 [9.2 (3.9-14.5)]	8 [7.8 (2.5-13.1)]	4 [4.8 (0.1-9.4)]	4 [6.1 (1.1-11.9)]	3 [4.6 (0.6-9.8)]	0.722
<b>Statin</b>	188 [22.9 (17.3-27.1)]	71 [26.2 (20.7-38.3)]	19 [17.1 (10.2-24.2)]	29 [24.2 (16.5-32.2)]	21 [20.6 (12.6-28.5)]	19 [22.6 (13.5-31.7)]	13 [19.7 (9.8-29.5)]	16 [24.6 (13.8-35.3)]	0.892
<b>Loop diuretic</b>	250 [30.5 (24.8-35.6)]	81 [29.9 (24.4-35.3)]	31 [27.4 (19.7-36.4)]	24 [20.0 (12.8-27.4)]	32 [31.4 (22.2-40.5)]	41 [48.8 (37.9-59.7)]	20 [30.3 (18.9-41.7)]	21 [32.3 (20.6-43.9)]	0.003
<b>Thiazide</b>	240 [29.3 (23.9-34.1)]	69 [25.5 (20.2-30.6)]	35 [27.5 (19.7-40.3)]	39 [32.5 (24.2-41.3)]	32 [31.4 (22.2-40.5)]	17 [20.2 (11.4-29)]	22 [33.3 (21.6-45)]	26 [40.0 (27.7-52.2)]	0.107
<b>Antiaggregant</b>	330 [40.3 (35.2-44.5)]	119 [43.9 (37.9-49.8)]	37 [33.3 (24.4-42.2)]	34 [28.3 (20.3-36.8)]	37 [36.3 (26.7-45.7)]	57 [67.9 (57.6-78)]	27 [40.9 (28.7-53.1)]	19 [29.2 (17.8-40.6)]	<0.001
<b>Anticoagulant</b>	240 [29.3 (25.4-34.5)]	85 [30.4 (25.8-35.9)]	24 [21.6 (13.8-29.4)]	50 [41.7 (32.6-50.4)]	42 [41.2 (32.2-50.1)]	12 [14.3 (6.6-21.9)]	21 [31.8 (20.2-43.3)]	6 [9.2 (2-16.4)]	<0.001
<b>Oral antihyperglysemic</b>	189 [23.1 (19.8-27.1)]	56 [18.5 (14.8-22.1)]	26 [23.4 (15.4-31.4)]	36 [30.0 (21.1-37.7)]	24 [23.5 (15.1-31.9)]	17 [20.2 (11.4-29)]	14 [21.2 (11-31.3)]	22 [33.8 (22-45.6)]	0.008

Data are presented as number and percentage (95% Confidence Interval). There are no missing data for all parameters.